STAT6 and fatty liver disease: In addition, rosiglitazone limited liver steatosis while enhancing adipose fat accumulation and insulin sensitivity in STAT6-deficient mice (Sajic et al., 2013), suggesting a complex interaction between STAT6 and PPAR-γ in the regulation of whole-body fat distribution.